Grant: Doctoral Research Award: Canada Graduate Scholarships
Université de Montréal
$105,000.00
Optimizing immunotherapy for breast cancer through co-targeting Glycoprotein NMB.
EF 2022-23
Résumé
Breast cancer (BC) is the leading cause of cancer-related deaths in women, mostly due to metastasis. Metastasis is the spreading of tumor cells from the breast to other organs in the body. There are several types of breast cancer and the triple negative breast cancer (TNBC) subtype has the worst prognosis for patients, accounting for 25% of breast cancer deaths. The poor outcome of TNBC patients is due to, in part, the lack of targeted therapies for this subtype of breast cancer. Immunotherapy is now the current standard of care for metastatic TNBC because these cancers have a high number of immune cells inside the tumors. While immunotherapy has improved the outcomes of patients with cancers such as melanoma and lung cancer, it is not as effective for TNBC for unknown reasons. Additional research is required to exploit immunotherapy to its full potential for patients with TNBC. We have identified a protein called Glycoprotein NMB (GPNMB), which is highly expressed by TNBC tumors, and is associated with aggressive metastatic disease and poor survival in patients. Our preliminary data suggests that, in the context of cancer, GPNMB suppresses the immune system, thereby preventing the immune cells from killing cancer cells. We therefore hypothesize that by blocking GPNMB we will increase the ability of immunotherapy to target TNBC. Using state-of-the-art imaging technology, I will compare the immune cell composition of TNBC tumors with or without GPNMB to understand how GPNMB suppresses immune cells within the tumor. I will then determine if blocking GPNMB enhances the ability of immunotherapy to target TNBC by treating mouse models with 1) immunotherapy, 2) a GPNMB inhibitor or 3) a combination of both Immunotherapy and a GPNMB inhibitor. My project might have significant implications for metastatic TNBC patients, as it could potentially allow all metastatic TNBC patients to benefit from immunotherapy and thus have improved prognostic outcomes.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
476260
Name
Lazaratos Anna-Maria
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Optimizing immunotherapy for breast cancer through co-targeting Glycoprotein NMB.
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Gpnmb; Imaging Mass Cytometry; Immune Checkpoint Inhibitors; Immunotherapy; Metastasis
Abstract
Breast cancer (BC) is the leading cause of cancer-related deaths in women, mostly due to metastasis. Metastasis is the spreading of tumor cells from the breast to other organs in the body. There are several types of breast cancer and the triple negative breast cancer (TNBC) subtype has the worst prognosis for patients, accounting for 25% of breast cancer deaths. The poor outcome of TNBC patients is due to, in part, the lack of targeted therapies for this subtype of breast cancer. Immunotherapy is now the current standard of care for metastatic TNBC because these cancers have a high number of immune cells inside the tumors. While immunotherapy has improved the outcomes of patients with cancers such as melanoma and lung cancer, it is not as effective for TNBC for unknown reasons. Additional research is required to exploit immunotherapy to its full potential for patients with TNBC. We have identified a protein called Glycoprotein NMB (GPNMB), which is highly expressed by TNBC tumors, and is associated with aggressive metastatic disease and poor survival in patients. Our preliminary data suggests that, in the context of cancer, GPNMB suppresses the immune system, thereby preventing the immune cells from killing cancer cells. We therefore hypothesize that by blocking GPNMB we will increase the ability of immunotherapy to target TNBC. Using state-of-the-art imaging technology, I will compare the immune cell composition of TNBC tumors with or without GPNMB to understand how GPNMB suppresses immune cells within the tumor. I will then determine if blocking GPNMB enhances the ability of immunotherapy to target TNBC by treating mouse models with 1) immunotherapy, 2) a GPNMB inhibitor or 3) a combination of both Immunotherapy and a GPNMB inhibitor. My project might have significant implications for metastatic TNBC patients, as it could potentially allow all metastatic TNBC patients to benefit from immunotherapy and thus have improved prognostic outcomes.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lazaratos, Anna-Maria
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~